Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE: Pembrolizumab in Advanced Solid Tumors
NCT02644369Phase 2Active, not recruiting
- Sponsor
- University Health Network
- Start
- Mar 2016
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), epithelial ovarian cancer (EOC), melanoma, solid tumor, sponsored by University Health Network. Started Mar 2016; status: active, not recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)triple-negative breast cancer (TNBC)epithelial ovarian cancer (EOC)melanomasolid tumor
Beyond the preview
Go deeper on NCT02644369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02644369.